Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 7Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Medulloblastoma 7Neuroblastoma 6Ganglioneuroblastoma 5Brain Neoplasms 5Triple Negative Breast Neoplasms 1Pinealoma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Trastuzumab 20Radiosurgery 15Magnetic Resonance Spectroscopy 15Capecitabine 14Lapatinib 12Radiotherapy 11Specimen Handling 10Cyclophosphamide 9trastuzumab deruxtecan 8Temozolomide 8Docetaxel 8Paclitaxel 7Gemcitabine 6Cisplatin 6sacituzumab govitecan 5Vinorelbine 5Therapeutics 5Spinal Puncture 5Flow Cytometry 5tucatinib 4pembrolizumab 4paclitaxel-Angiopep-2 conjugate 4eribulin 4Methotrexate 4Irinotecan 4Fluorodeoxyglucose F18 4Dexamethasone 4Bevacizumab 4temsirolimus 3pyrotinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Platinum × CNS × Clear all
NCT02595905 2026-04-08

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

National Cancer Institute (NCI)

Phase 2 Completed
344 enrolled 11 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡